Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT 1:15:56 PM EDT
| Market Cap (Intraday) | 1.57B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 3041 |
| 10-Day MA | $64.13 |
| 50-Day MA | $74.29 |
| 200-Day MA | $51.38 |
Arcturus Therapeutics Ltd. Stock, NASDAQ:ARCT
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA 92121
Israel
Phone: 858-900-2660
Number of Employees: 72
Description
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.